Steve Carlin
Shoppers Drug Mart Corp
SC-T
DON'T BUY
Oct 31, 2012
Stock has been pretty dead for the last couple of years. Have some challenges on the profitability side. Notwithstanding the fact that they continue to roll out new stores and grow their square footage they have been very challenged on the prescription side due to some regulatory legislative changes. Stock has never been a cheap stock and he doesn’t see a whole lot of upside. 2.5% dividend yield.
$61.29 is full value. Loblaw’s is fairly fully valued. There is too much competition, even if Target is struggling in Canada. Prefers THI-T but it is fully valued. Same with Canadian Tire or Sears. Dollarama would be a better entry point.
(A Top Pick May 16/13. Up 29.79%.) Sold his holdings in October because the transaction by Loblaw’s (L-T) involved quite a few shares being swapped and he did not want exposure to food retailing.
2.36% bond maturing May 24/18. A company that you don’t get many choices to buy in the consumer area. Credit quality is good at A minus and the yield spread is attractive.
(A Top Pick June 19/13. Up 27.54%.) Had not been expecting the takeout by Loblaws (L-T), but just bought this because it was a quality retailer generating a lot of free cash flow and paying down their debts.
(Top Pick May 16/13, Up 34.12%)He did not keep the Loblaw’s shares because he did not want to be exposed to food retailers. He is now sitting on the cash from this.
(A Top Pick Jan 29/14. Up 2.96%.) 2.36% bond maturing May 24/18. This has rolled down the curve with a positive return of over 3%. It will continue to generate positive returns.
(Past Top Pick June 6, 2014, Bond matures May 24,2018, up 3.79%) Had a good balance sheet, but folded into Loblaws now, Performed well. Most bonds yields have been going sideways since late 2014.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.
Stock has been pretty dead for the last couple of years. Have some challenges on the profitability side. Notwithstanding the fact that they continue to roll out new stores and grow their square footage they have been very challenged on the prescription side due to some regulatory legislative changes. Stock has never been a cheap stock and he doesn’t see a whole lot of upside. 2.5% dividend yield.